News

Concept Medical’s fourth IDE approval for the MagicTouch Sirolimus Coated Balloon is granted for the treatment of Superficial Femoral Artery Disease (SFA) Latin America – español USA – English Middle East – English USA – español Brazil – Português

by

TAMPA, Fla., May 29, 2023 /PRNewswire/ — The US FDA, on the 24th of May 2023, granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc’s Sirolimus Coated Balloon (SCB) MagicTouch PTA for the treatment of Superficial Femoral Arteries (SFA). This marks the fourth IDE approval for the Company’s Sirolimus coated balloon. The Company has … Read more

Urinalysis Market Anticipated to Garner $5,719.3 Million, Growing at a 6.4% CAGR in the 2022-2031 Timeframe [280-Pages]

by

The global urinalysis market is expected to grow primarily due to the expansion of the healthcare system. Disease screening sub-segment is expected to flourish immensely. The market in the North America region is predicted to grow at a high CAGR by 2031. NEW YORK, May 29, 2023 /PRNewswire/ — Global Urinalysis Market Forecast Analysis: As … Read more

Lung Cancer Therapies Market to Amplify Significantly over 2022-2029

by

LONDON , May 29, 2023 /PRNewswire/ — Lung cancer has emerged as one of the most commonly occurring ailments across the globe. This deadly disease has a high number of mortality rates. Patients affected with this disease experience difficulties in breathing, cough, chest pain, and other severe symptoms due to the inability of lungs to supply … Read more

Hummingbird Bioscience Announces HMBD-002 Trials in Progress Poster at ASCO Annual Meeting 2023

by

HMBD-002, a non-depleting, high-affinity anti-VISTA antibody, possesses key design features enabling robust anti-tumor activity in preclinical models, positioning it as a potentially important new therapy for VISTA-expressing cancers including triple-negative breast cancer and non-small cell lung cancer HMBD-002 is currently being assessed in a Phase 1 study to determine the recommended Phase 2 dose as … Read more

AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer

by

HIGHLIGHTS Amplia’s highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic cancer FOLFIRINOX is the most widely used treatment for pancreatic cancer patients in the US, Canada and most European countries This new data supports clinical studies investigating the combination of AMP945 in a second … Read more

ABIOGEN PHARMA COMPLETES THE ACQUISITION OF EFFRX

by

PISA, Italy, May 29, 2023 /PRNewswire/ — Abiogen Pharma S.p.A., Italian leading company in the field of osteoarticular and bone metabolism diseases, is pleased to announce the acquisition of a 97,09% stake in EffRx Pharmaceuticals SA, a Swiss company that develops and markets prescription drugs targeted in particular to musculoskeletal and rare pathologies on European … Read more

ABIOGEN PHARMA FINALISE L’ACQUISITION D’EFFRX

by

PISE, Italie, 29 mai 2023 /PRNewswire/ — Abiogen Pharma S.p.A., société italienne leader dans le domaine des maladies ostéo-articulaires et du métabolisme osseux, a le plaisir d’annoncer l’acquisition d’une participation de 97,09 % dans EffRx Pharmaceuticals SA, une société suisse qui développe et commercialise des médicaments sur ordonnance ciblant en particulier les pathologies musculo-squelettiques et rares … Read more

ABIOGEN PHARMA COMPLETES THE ACQUISITION OF EFFRX

by

PISA, Italy, May 29, 2023 /PRNewswire/ — Abiogen Pharma S.p.A., Italian leading company in the field of osteoarticular and bone metabolism diseases, is pleased to announce the acquisition of a 97,09% stake in EffRx Pharmaceuticals SA, a Swiss company that develops and markets prescription drugs targeted in particular to musculoskeletal and rare pathologies on European … Read more

Abiogen Pharma finaliza la adquisición de EffRx

by

PISA, Italia, 29 de mayo de 2023 /PRNewswire/ — Abiogen Pharma S.p.A., empresa italiana líder en el campo de las enfermedades osteoarticulares y del metabolismo óseo, se complace en anunciar la adquisición de una participación del 97,09% en EffRx Pharmaceuticals SA, una empresa suiza que desarrolla y comercializa medicamentos de prescripción dirigidos en particular a patologías … Read more

ABIOGEN PHARMA SCHLIESST DIE ÜBERNAHME VON EFFRX AB

by

PISA, Italien, 29. Mai 2023 /PRNewswire/ — Abiogen Pharma S.p.A., italienisches führendes Unternehmen auf dem Gebiet der Osteoartikulären Erkrankungen und Knochenstoffwechselerkrankungen, freut sich, den Erwerb eines Anteils von 97,09 % an EffRx Pharmaceuticals SA bekannt zu geben. EffRx Pharmaceuticals SA ist ein Schweizer Unternehmen, das verschreibungspflichtige Arzneimittel entwickelt und vertreibt, die insbesondere auf Erkrankungen des Bewegungsapparats … Read more